Primary cutaneous follicle centre lymphoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]

The predominant therapy for primary cutaneous follicle centre lymphoma is radiotherapy. Adjunctive chemotherapy may be required.

• Surgical removal and/or radiotherapy is given for localized disease.^[1][2]
• Radiation using multiple radiation fields is given if the disease has wider extent with grouped lesions.^{[1]:314[3][4][2]}
• For the less common situation of more extensive disease (still confined to skin), rituximab without chemotherapy is used.^[1][3][4][2]Intralesional interferon alpha (IFN-α)^[5]and intralesional rituximab have been used.^[1][5]
• There are mixed results of CHOP and R-CHOP. In one study on 104 patients CHOP chemotherapy demonstrated complete responses in 85 percent of the patients.^[6]
• There are also published case reports presented clinical responses to topical class 1 corticosteroids.^[7]
• Approximately one-third of primary cutaneous follicle centre lymphoma relapse, usually in the skin; treatment is similar to initial management^[2] and overall survival remains excellent.^[8]

Template:WikiDoc Sources